Literature DB >> 14673955

Difference of cancer core distribution between first and repeat biopsy: In patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy.

Tsuyoshi Furuno1, Takayoshi Demura, Tatsuo Kaneta, Hiroko Gotoda, Shunji Muraoka, Toshihiro Sato, Satoshi Nagamori, Nobuo Shinohara, Tomohiko Koyanagi.   

Abstract

BACKGROUND: We performed extensive transperineal ultrasound guided template prostate biopsy and evaluated cancer core distribution.
METHODS: From August 2000 to May 2002, 113 men with prostate specific antigen levels between 4.0 and 10.0 ng/ml underwent template biopsy. Eighty-six had no previous biopsy (first group) and 27 had previous transrectal sextant biopsies (repeat group). A mean of 18.4 biopsy cores were taken. We defined the region over 2 cm from the rectal face of the prostate as the anterior region and the other as the posterior.
RESULTS: Cancer was detected in 49 of 113 (43%) men. Forty-two were in the first group and seven in the repeat group. In the first group, the cancer core rate (cancer core number/biopsy core number) in the anterior region (7.0%) had no difference from that in the posterior region (8.6%) (P = 0.7111). But in the repeat group, the cancer core rate in the anterior region (4.6%) was higher than in the posterior (1.5%) (P < 0.0001).
CONCLUSIONS: These results suggest that transrectal sextant biopsies miss more cancers in the anterior region than in the posterior. We believe template technique has an advantage to be able to detect cancer equally in the anterior and posterior. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14673955     DOI: 10.1002/pros.10298

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

1.  Focal therapy: a new paradigm for the treatment of prostate cancer.

Authors:  Basir Tareen; Guilherme Godoy; Samir S Taneja
Journal:  Rev Urol       Date:  2009

Review 2.  Is it time to consider a role for MRI before prostate biopsy?

Authors:  Hashim U Ahmed; Alex Kirkham; Manit Arya; Rowland Illing; Alex Freeman; Clare Allen; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

Review 3.  Transperineal biopsy of the prostate--is this the future?

Authors:  Dwayne T S Chang; Benjamin Challacombe; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2013-09-24       Impact factor: 14.432

4.  Management of low-risk prostate cancer.

Authors:  Robert A Gardiner; Freddie C Hamdy
Journal:  World J Urol       Date:  2008-09-19       Impact factor: 4.226

5.  [Metastasis of prostate carcinoma to the lamina submucosa of the distal rectum in ulcerative colitis 2 years after transrectal prostate biopsy and radical prostatovesiculectomy].

Authors:  J Bernhardt; C Letzkus; M Kind; H B Reith; N Pfitzenmaier
Journal:  Urologe A       Date:  2005-01       Impact factor: 0.639

Review 6.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

Review 7.  Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?

Authors:  Hashim Uddin Ahmed; Mark Emberton
Journal:  World J Urol       Date:  2008-08-14       Impact factor: 4.226

8.  Beyond diagnosis: evolving prostate biopsy in the era of focal therapy.

Authors:  J L Dominguez-Escrig; S R C McCracken; D Greene
Journal:  Prostate Cancer       Date:  2010-12-09

9.  Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting.

Authors:  A V Taira; G S Merrick; R W Galbreath; H Andreini; W Taubenslag; R Curtis; W M Butler; E Adamovich; K E Wallner
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-09-29       Impact factor: 5.554

10.  Repeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy.

Authors:  Adam W Nelson; Rebecca C Harvey; Richard A Parker; Christof Kastner; Andrew Doble; Vincent J Gnanapragasam
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.